Aprotinin

When ATH:
B02AB01

Characteristic.

Antienzyme drug, obtained from the authorities (Light et al.) cattle, polyvalent proteinase inhibitor.

Activity is expressed in various aprotinin units: KYA-kallikrein inactivate units; Ph. EUR. U-trypsin inactivate units of the European Pharmacopoeia, 1 Ph.Eur.U соответствует 1800 KIE; System-antitripsinovye units, 1 Atreus matches 1,33 KIE; U-the unit of enzyme on the State Pharmacopoeia of the USSR.

Pharmacological action.
Antifibrinolytic, hemostatic, antiproteoliticheskoe.

Application.

Pancreatitis (sharp, exacerbation of chronic, prevention of postoperative), pankreonekroz, bleeding giperfibrinoliticheskie-post-traumatic, postoperative (especially in prostatic surgery, light), before, during and after childbirth, complications of thrombolytic therapy, open-heart surgery with the use of cardiopulmonary bypass machines, and others., treatment and prevention of various forms of shock (endotoxic, traumatic, hemolytic), posleoperatsionnыy mumps.

Contraindications.

Hypersensitivity, ICE syndrome, pregnancy (I trimester), lactation.

Pregnancy and breast-feeding.

It contraindicated in I trimester of pregnancy (in the II and III trimester only if absolutely necessary).

Category actions result in FDA - B. (The study of reproduction in animals revealed no risk of adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not done.)

At the time of treatment should stop breastfeeding.

Side effects.

From the nervous system and sensory organs: hallucinations, confusion, psychoses.

Cardio-vascular system and blood (hematopoiesis, hemostasis): hypotension, tachycardia.

Other: bronchospasm, Allergic (skin rash) and anaphylactic (up to anaphylactic shock) reaction; with the rapid introduction-nausea, vomiting; with a long introduction-thrombophlebitis at the injection site.

Cooperation.

Pharmaceutically incompatible with other drugs (with the exception of electrolytes and glucose). Lowers the activity of fibrinolytic funds, incl. streptokinase, urokinase.

Dosing and Administration.

B / (slowly), bolus or infusion. Dose picked individually, depending on the condition of the patient.

When pancreatitis: in acute pancreatitis-1000000-300000 KYA/day within 2-6 h 9, exacerbation of chronic-25000-50000 KYA/day for 3-6 h 9, for the prevention of traumatic pancreatitis — 200000 KYA before surgery and 100000 KIE every 6 hours after intervention.

When giperfibrinoliticheskih coagulopathies administered in high doses (1 million KYA and more).

Violations hemostasis in children administered at a dose of 20000 KIU / kg / day.

During long minor bleeding possible local use in dose 100000 KYA as impregnated with solution of the drug wipes.

In shock: in the initial dose of 300000-400000 KYA, then 200000 KYA in/in struino every 4 no.

Precautions.

In/in introducing only in lying position. Before applying, you must conduct a skin test to detect possible individual hypersensitivity. The caution should appoint persons, prone to allergic reactions, and patients, that for 2-3 days before receiving muscle relaxants. With the development of anaphylactic reactions administration immediately cease and conduct appropriate therapy.

Cautions.

Comparison, conducted by objective methods (determining the amount of aprotinin to the trypsin activity and HPLC), shows, what 1 amp. 15 U ingitrila is equal to 1 amp. 10000 Atre kontrikala.

Cooperation